Abbott Laboratories
NYSE:ABT

Watchlist Manager
Abbott Laboratories Logo
Abbott Laboratories
NYSE:ABT
Watchlist
Price: 117.65 USD -0.8% Market Closed
Market Cap: 204.7B USD
Have any thoughts about
Abbott Laboratories?
Write Note

Wall Street
Price Targets

ABT Price Targets Summary
Abbott Laboratories

Wall Street analysts forecast ABT stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ABT is 132.14 USD with a low forecast of 106.28 USD and a high forecast of 153.3 USD.

Lowest
Price Target
106.28 USD
10% Downside
Average
Price Target
132.14 USD
12% Upside
Highest
Price Target
153.3 USD
30% Upside

ABT Last Price Targets
Abbott Laboratories

The latest public price target was made on Oct 17, 2024 by Adam Maeder from Piper Sandler , who expects ABT stock to rise by 13% over the next 12 months. You can read more about this price target by viewing the article on StreetInsider.

Analyst Price Target Date Article
Adam Maeder
Piper Sandler
133 USD
Upside 13%
2 weeks ago
Oct 17, 2024
Abbott Labs (ABT) PT Raised to $133 at Piper Sandler
StreetInsider
Lee Hambright
Bernstein
138 USD
Upside 17%
2 weeks ago
Oct 17, 2024
Abbott price target raised to $138 from $133 at Bernstein
TheFly
Matthew Taylor
Jefferies
125 USD
Upside 6%
2 weeks ago
Oct 16, 2024
Abbott Labs (ABT) PT Raised to $125 at Jefferies
StreetInsider
Vijay Kumar
Evercore ISI
128 USD
Upside 9%
2 weeks ago
Oct 16, 2024
Abbott Labs (ABT) PT Raised to $128 at Evercore ISI
StreetInsider
Marie Thibault
BTIG
139 USD
Upside 18%
2 weeks ago
Oct 16, 2024
Abbott Labs (ABT) PT Raised to $139 at BTIG
StreetInsider
Charles Minervino
Susquehanna
120 USD
Upside 2%
4 weeks ago
Oct 8, 2024
This Abbott Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Benzinga
Shagun Singh
RBC Capital
130 USD
Upside 10%
4 weeks ago
Oct 8, 2024
Abbott price target raised to $130 from $125 at RBC Capital
TheFly
Suraj Kalia
Oppenheimer
130 USD
Upside 10%
4 weeks ago
Oct 8, 2024
This Abbott Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Benzinga
Jonathan Atkin
RBC Capital
345 USD
Upside 193%
1 month ago
Sep 19, 2024
This Abbott Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Benzinga
Scott Fortune
Roth Capital
50 USD
Downside 58%
1 month ago
Sep 19, 2024
This Abbott Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Benzinga
Adam Maeder
Piper Sandler
131 USD
Upside 11%
1 month ago
Sep 19, 2024
Abbott initiated with an Overweight at Piper Sandler
TheFly
Matthew Taylor
Jefferies
120 USD
Upside 2%
2 months ago
Aug 27, 2024
Jefferies Reiterates Hold Rating on Abbott Labs (ABT)
StreetInsider
Joanne Wuensch
Citigroup
127 USD
Upside 8%
2 months ago
Aug 22, 2024
Abbott price target raised to $127 from $119 at Citi
TheFly
Jayson Bedford
Raymond James
127 USD
Upside 8%
3 months ago
Jul 18, 2024
Abbott Gears Up For Q2 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Benzinga
Joanna Wiensch
Citigroup
119 USD
Upside 1%
3 months ago
Jul 18, 2024
Abbott Gears Up For Q2 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Benzinga
Vijay Kumar
Evercore ISI
120 USD
Upside 2%
4 months ago
Jul 2, 2024
Abbott price target lowered to $120 from $125 at Evercore ISI
TheFly
Marie Thibault
BTIG
135 USD
Upside 15%
5 months ago
Jun 3, 2024
BTIG Reiterates Buy Rating on Abbott Labs (ABT)
StreetInsider
David Roman
Goldman Sachs
121 USD
Upside 3%
5 months ago
May 30, 2024
Goldman Sachs Starts Abbott Labs (ABT) at Buy
StreetInsider
Matt Miksic
Barclays
140 USD
Upside 19%
6 months ago
Apr 22, 2024
Abbott Labs (ABT) PT Lowered to $140 at Barclays
StreetInsider
Lee Hambright
Bernstein
133 USD
Upside 13%
6 months ago
Apr 18, 2024
Abbott Q1 strong but still in penalty box on litigation overhang, says Bernstein
TheFly
Shagun Singh
RBC Capital
125 USD
Upside 6%
6 months ago
Apr 18, 2024
Abbott Labs (ABT) PT Lowered to $125 at RBC Capital
StreetInsider
Show More Price Targets
Show Less Price Targets
Adam Maeder
Piper Sandler
Price Target 133 USD
Upside/Downside 13%
View Source
Lee Hambright
Bernstein
Price Target 138 USD
Upside/Downside 17%
View Source
Matthew Taylor
Jefferies
Price Target 125 USD
Upside/Downside 6%
View Source
Vijay Kumar
Evercore ISI
Price Target 128 USD
Upside/Downside 9%
View Source
Marie Thibault
BTIG
Price Target 139 USD
Upside/Downside 18%
View Source
Charles Minervino
Susquehanna
Price Target 120 USD
Upside/Downside 2%
View Source
Shagun Singh
RBC Capital
Price Target 130 USD
Upside/Downside 10%
View Source
Suraj Kalia
Oppenheimer
Price Target 130 USD
Upside/Downside 10%
View Source
Jonathan Atkin
RBC Capital
Price Target 345 USD
Upside/Downside 193%
View Source
Scott Fortune
Roth Capital
Price Target 50 USD
Upside/Downside 58%
View Source
Adam Maeder
Piper Sandler
Price Target 131 USD
Upside/Downside 11%
View Source
Matthew Taylor
Jefferies
Price Target 120 USD
Upside/Downside 2%
View Source
Joanne Wuensch
Citigroup
Price Target 127 USD
Upside/Downside 8%
View Source
Jayson Bedford
Raymond James
Price Target 127 USD
Upside/Downside 8%
View Source
Joanna Wiensch
Citigroup
Price Target 119 USD
Upside/Downside 1%
View Source
Vijay Kumar
Evercore ISI
Price Target 120 USD
Upside/Downside 2%
View Source
Marie Thibault
BTIG
Price Target 135 USD
Upside/Downside 15%
View Source
David Roman
Goldman Sachs
Price Target 121 USD
Upside/Downside 3%
View Source
Matt Miksic
Barclays
Price Target 140 USD
Upside/Downside 19%
View Source
Lee Hambright
Bernstein
Price Target 133 USD
Upside/Downside 13%
View Source
Shagun Singh
RBC Capital
Price Target 125 USD
Upside/Downside 6%
View Source
Show More Price Targets
Show Less Price Targets
Abbott Laboratories Competitors:
Price Targets
AORT
Artivion Inc
13% Upside
335890
Viol Co Ltd
63% Upside
2235
MicroTech Medical Hangzhou Co Ltd
9% Upside
ATRC
AtriCure Inc
25% Upside
PRN
Profound Medical Corp
44% Upside
MLSS
Milestone Scientific Inc
168% Upside
300298
Sinocare Inc
20% Upside
GMED
Globus Medical Inc
9% Upside

Revenue
Forecast

Revenue Estimate
Abbott Laboratories

For the last 8 years the compound annual growth rate for Abbott Laboratories's revenue is 9%. The projected CAGR for the next 3 years is 7%.

9%
Past Growth
7%
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Abbott Laboratories

For the last 8 years the compound annual growth rate for Abbott Laboratories's operating income is 11%. The projected CAGR for the next 3 years is 20%.

11%
Past Growth
20%
Estimated Growth
Estimates Accuracy
-26%
Average Miss

Net Income
Forecast

Net Income Estimate
Abbott Laboratories

For the last 8 years the compound annual growth rate for Abbott Laboratories's net income is 3%. The projected CAGR for the next 3 years is 21%.

3%
Past Growth
21%
Estimated Growth
Estimates Accuracy
-28%
Average Miss

See Also

Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is ABT's stock price target?
Price Target
132.14 USD

According to Wall Street analysts, the average 1-year price target for ABT is 132.14 USD with a low forecast of 106.28 USD and a high forecast of 153.3 USD.

What is Abbott Laboratories's Revenue forecast?
Projected CAGR
7%

For the last 8 years the compound annual growth rate for Abbott Laboratories's revenue is 9%. The projected CAGR for the next 3 years is 7%.

What is Abbott Laboratories's Operating Income forecast?
Projected CAGR
20%

For the last 8 years the compound annual growth rate for Abbott Laboratories's operating income is 11%. The projected CAGR for the next 3 years is 20%.

What is Abbott Laboratories's Net Income forecast?
Projected CAGR
21%

For the last 8 years the compound annual growth rate for Abbott Laboratories's net income is 3%. The projected CAGR for the next 3 years is 21%.

Back to Top